ArticleAnnals of medicine2025
The application of KI.C57-ras2.0 mouse in the carcinogenicity evaluation of medical devices-carcinogenicity evaluation of a novel hemodialyzer.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAlternative transgenic mouse models, such as rasH2, have been developed as to replace the traditional 2-year rodent carcinogenicity study. However, due to high cost, reliance on imports, and unpredictable supply chains, these transgenic mouse models have not yet been widely adopted for carcinogenicity evaluations of medical devices in China.
methodsKI.C57-ras2.0 mice, which possess independent intellectual property rights in China, were employed to evaluate the carcinogenicity of a new hemodialyzer. A total of 110 KI.C57-ras2.0 mice were divided into three groups including positive control (PC) group, negative control (NC) group and sample extracts (SE) group. Animals in the PC group were injected with MNU intraperitoneally at the concentration of 75 mg/kg for a single time. Animals in the SE and NC group were injected intraperitoneally with sample solution and 0.9% sodium chloride, the injection volume was 20 ml/kg BW, 6 days per week, and the entire administration period was 26 weeks.
resultsThe survival rates of mice in PC group, NC group and SE group were 16.7%, 93.3% and 92.0%, respectively. Tumour incidence rates were 100.00%, 13.33% and 12.00%; the incidences of benign tumour were 10.00%, 3.33% and 6.00%; the incidences of malignant tumour were 90.00%, 10.00% and 6.00%; the incidences of multiple tumour was 86.67%, 0.00% and 0.00%; the average number of tumours were 8.67 ± 5.97, 0.10 ± 0.31 and 0.10 ± 0.30, respectively. There was no statistical difference in the above indexes between SE group and NC group, and there was no significant correlation between tumour lesions of all genders in SE group. Therefore, there is no carcinogenicity in this hemodialyzer.
conclusionsThis new hemodialyzer had no carcinogenicity under this experimental condition. This study also improved the biological evaluation system of medical devices. As an animal model with great application prospects, we believe that KI.C57-ras2.0 mice will be an indispensable model animal for the evaluation of medical devices in the future, and facilitated the marketing of new biomaterials and medical devices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.